FDA Commissioner Martin Makary introduced a pilot Commissioner’s National Priority Voucher program aimed at drastically reducing drug review times for products meeting defined U.S. national interests. This initiative proposes accelerated final application reviews within 1–2 months, compared to the standard 10–12 months, with eligibility requiring early submission of key application components and ongoing communication with FDA staff. The FDA emphasizes modernizing and streamlining regulatory processes without cutting scientific rigor, reinforcing efficiency and expedited access to innovative therapies amid international competition.